17-80113002-G-T
Variant summary
Our verdict is Pathogenic. The variant received 17 ACMG points: 17P and 0B. PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000152.5(GAA):c.2015G>T(p.Arg672Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R672Q) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000152.5 missense
Scores
Clinical Significance
Conservation
Publications
- glycogen storage disease IIInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), PanelApp Australia, ClinGen, G2P
- glycogen storage disease due to acid maltase deficiency, infantile onsetInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- glycogen storage disease due to acid maltase deficiency, late-onsetInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 17 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GAA | NM_000152.5 | c.2015G>T | p.Arg672Leu | missense_variant | Exon 14 of 20 | ENST00000302262.8 | NP_000143.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| GAA | ENST00000302262.8 | c.2015G>T | p.Arg672Leu | missense_variant | Exon 14 of 20 | 1 | NM_000152.5 | ENSP00000305692.3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Glycogen storage disease, type II Pathogenic:2
The NM_000152.5:c.2015G>T variant in GAA is a missense variant that results in the substitution of an arginine for a leucine at amino acid 672 (p.Arg672Leu). One Indian patient with late onset Pompe disease has been reported, with <1% normal GAA activity in skin fibroblasts, and muscle histology consistent with the condition (PMID: 33741225) (PP4_Moderate). This individual is compound heterozygous for the variant and another variant in GAA that has been classified as likely pathogenic for Pompe disease by the ClinGen LD VCEP, c.2783A>G (p.Tyr928Cys); phase unconfirmed (0.25 points) (Insufficient to apply PM3). The variant is absent in gnomAD v4.1.0. (PM2_Supporting). Two other variants at the same amino acid position have been classified as pathogenic (c.2014C>T, p.Arg672Trp, ClinVar Variation ID: 188773) or likely pathogenic (c.2015G>A p.Arg672Gln, ClinVar Variation ID: 371126) for Pompe disease by the ClinGen LD VCEP (PM5). The computational predictor REVEL gives a score of 0.955 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). SpliceAI predicts no impact on splicing. There is a ClinVar entry for this variant (Variation ID: 2675756) with one submitter classifying the variant as pathogenic. In summary, these variant meets the criteria to be classified a likely pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LD VCEP (Specifications Version 2.0.0.): PM5, PP4_Moderate, PP3, PM2_Supporting (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel, August 31, 2025)
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at